Skip to main content
. 2016 Oct 8;7(47):76793–76805. doi: 10.18632/oncotarget.12529

Figure 7. Effects of tofacitinib on JAK3/STAT5 pathway components and growth in EBV-infected cells isolated from patients with EBV-associated T cell lymphoma.

Figure 7

(A) γδ T cells and peripheral blood mononuclear cells (PBMCs) were treated with 1 μM tofacitinib for 24 h and cell lysates were immunoblotted for the indicated proteins. (B) γδ T cells isolated from patients with EBV-associated T cell lymphoma were treated with the indicated concentrations of tofacitinib, and viable cells were counted using the trypan blue exclusion test. *P < 0.05 as compared with DMSO-treated cells. (C) PBMCs isolated from a patient with EBV-associated T cell lymphoma or from a healthy donor (control) were treated with the indicated concentrations of tofacitinib, and viable cells were counted using the trypan blue exclusion test. Values are means ± SE of the results from triplicate experiments using patient samples. *P < 0.05 as compared with DMSO-treated cells.